Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jul;23(7):668-75.
doi: 10.1089/hum.2012.116.

Gene therapy for primary immunodeficiencies

Christine Rivat  1 , Giorgia Santilli, H Bobby Gaspar, Adrian J Thrasher
Affiliations
Review

Gene therapy for primary immunodeficiencies

Christine Rivat et al. Hum Gene Ther. 2012 Jul.

Abstract

For over 40 years, primary immunodeficiencies (PIDs) have featured prominently in the development and refinement of human allogeneic hematopoietic stem cell transplantation. More recently, ex vivo somatic gene therapy using autologous cells has provided remarkable evidence of clinical efficacy in patients without HLA-matched stem cell donors and in whom toxicity of allogeneic procedures is likely to be high. Together with improved preclinical models, a wealth of information has accumulated that has allowed development of safer, more sophisticated technologies and protocols that are applicable to a much broader range of diseases. In this review we summarize the status of these gene therapy trials and discuss the emerging application of similar strategies to other PIDs.

PubMed Disclaimer

References

    1. Aiuti A. Slavin S. Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. - PubMed
    1. Aiuti A. Cassani B. Andolfi G., et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 2007;117:2233–2240. - PMC - PubMed
    1. Aiuti A. Cattaneo F. Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009;360:447–458. - PubMed
    1. Avedillo Diez I. Zychlinski D. Coci E.G., et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol. Pharm. 2011;8:1525–1537. - PubMed
    1. Bauer T.R., Jr. Hickstein D.D. Gene therapy for leukocyte adhesion deficiency. Curr. Opin. Mol. Ther. 2000;2:383–388. - PubMed

Publication types